Esperion Therapeutics Inc. (NASDAQ:ESPR) shares dropped 4.5% on Tuesday . The stock traded as low as $10.90 and last traded at $10.93, with a volume of 99,868 shares traded. The stock had previously closed at $11.44.

ESPR has been the topic of several analyst reports. Lake Street Capital cut their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, June 29th. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. WallachBeth Capital cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a report on Tuesday, July 5th. JMP Securities restated a “buy” rating and set a $67.00 price target on shares of Esperion Therapeutics in a report on Thursday, June 16th. Finally, Credit Suisse Group AG cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $23.00 to $10.00 in a report on Wednesday, June 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. Esperion Therapeutics currently has an average rating of “Hold” and an average target price of $25.47.

The stock’s 50 day moving average is $14.25 and its 200-day moving average is $15.82. The firm’s market cap is $257.77 million.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. On average, equities research analysts expect that Esperion Therapeutics Inc. will post ($3.57) EPS for the current year.

In other news, Director Mark E. Mcgovern acquired 5,000 shares of Esperion Therapeutics stock in a transaction on Wednesday, July 6th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the purchase, the director now owns 600 shares in the company, valued at $6,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Timothy M. Mayleben acquired 7,000 shares of Esperion Therapeutics stock in a transaction on Wednesday, May 4th. The shares were purchased at an average price of $14.85 per share, with a total value of $103,950.00. Following the completion of the purchase, the chief executive officer now owns 41,614 shares in the company, valued at approximately $617,967.90. The disclosure for this purchase can be found here.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.